据报道,通过调节1-,5-和6-位侧链的大小,发现了基于3-氨基甲酰基-2-吡啶酮衍生物的新型CB2配体。该模板周围的结构-活性关系导致鉴定出S-777469为选择性CB2受体激动剂,该化合物在1.0 mg / kg po和10 mg / kg po下表现出对化合物48/80诱导的刮擦的显着抑制作用(55 %和61%)。
The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I):
wherein R
1
is optionally substituted C1-C8 alkyl and the like; R
2
is C1-C6 alkyl; R
3
is C1-C6 alkyl and the like; or R
2
and R
3
taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R
4
is hydrogen and the like; G is a group selected from the groups shown by the formula an the like:
wherein R
5
is hydrogen and the like; X
1
is a single bond and the like; X
2
is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R
6
)—, wherein R
6
is hydrogen and the like, and the like; X
3
is a single bond and the like;
a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.
The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I):
wherein R
1
, R
2
, R
3
, R
4
, and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.